GLAUKOS Corp GKOS

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived NYSE

Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012. In 2024, we commenced commercialization activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. We also offer commercially proprietary bio-activated pharmaceutical therapies for the treatment of corneal disorders. Beyond our approved products, we continue to develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Last close 178.88 2026-10-23
Market cap $10.55B 2026-06-30 share count
52-week range 73.16 - 191.62

Valuation FY2025 figures against the last close

P/S20.8x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.28

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • International
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 375M (73.9%) 74% United States International, FY2025: 132.4M (26.1%) 26% International FY2024 United States, FY2024: 270.1M (70.4%) 70% International, FY2024: 113.4M (29.6%) 30% FY2023 United States, FY2023: 219.4M (69.7%) 70% International, FY2023: 95.3M (30.3%) 30%
Region FY2025FY2024FY2023
United States $375.0M $270.1M $219.4M
International $132.4M $113.4M $95.3M

As the company reported it, from the “Revenue from Contracts with Customers - Disaggregation of Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $507.4M$383.5M$314.7M$282.9M$294.0M$225.0M$237.0M$181.3M$159.3M$114.4M
Cost of revenue $111.8M$94.0M$75.6M$69.0M$66.6M$91.7M$38.6M$25.1M$21.1M$16.2M
Gross profit $282.8M$289.5M$239.1M$213.9M$227.4M$133.2M$198.4M$156.2M$138.2M$98.2M
R&D ———————$49.7M$38.9M$29.2M
SG&A $331.7M$261.2M$224.1M$192.9M$179.3M$171.4M$176.6M$119.5M$96.3M$64.8M
Total operating expenses $482.4M$411.8M$367.8M$296.2M$260.3M$256.8M$248.7M$169.2M$140.5M$94.0M
Operating income -$199.6M-$122.4M-$128.7M-$82.3M-$32.9M-$123.6M-$50.3M-$13.0M-$2.3M$4.2M
Interest expense $4.6M$10.0M$13.6M$13.7M$13.4M$14.1M$2.6M———
Pre-tax income -$193.0M-$145.6M-$133.7M-$98.4M-$49.3M-$132.3M-$50.0M-$12.4M$1.0K$4.6M
Income tax $5.4M$771.0K$934.0K$766.0K$326.0K$12.0M$65.5M$583.0K$93.0K$43.0K
Net income -$187.7M-$146.4M-$134.7M-$99.2M-$49.6M-$120.3M$15.4M-$13.0M-$92.0K$4.5M
EPS, basic -3.28-2.77-2.78-2.09-1.07-2.700.41-0.370.000.14
EPS, diluted -3.28-2.77-2.78-2.09-1.07-2.700.37-0.370.000.12
Shares, diluted (wtd. avg.) 57.2M52.8M48.4M47.4M46.4M44.5M41.1M35.3M34.4M36.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $90.8M$169.6M$93.5M$126.6M$110.1M$106.2M$71.8M$38.6M$24.5M$6.6M
Receivables $108.6M$60.7M$39.9M$36.1M$33.4M$36.1M$38.4M$18.7M$16.7M$14.3M
Inventory $63.6M$57.7M$42.0M$37.8M$23.0M$15.8M$42.6M$13.3M$11.2M$6.8M
Total current assets $475.0M$449.8M$395.5M$443.9M$486.1M$469.4M$262.9M$176.6M$149.5M$120.0M
Property, plant and equipment $113.3M$97.9M$103.2M$94.4M$69.0M$24.0M$22.1M$19.2M$11.8M$7.6M
Goodwill $66.7M$66.1M$66.1M$66.1M$66.1M$66.1M$66.1M———
Other intangibles $141.9M$263.4M$283.0M$307.9M$332.8M$357.7M$382.6M—$3.1M$6.6M
Total assets $893.5M$974.8M$940.4M$1.00B$1.05B$1.01B$818.4M$207.0M$165.8M$134.4M
Accounts payable $24.6M$13.0M$13.4M$14.4M$7.3M$4.4M$5.8M$6.3M$6.2M$3.0M
Total current liabilities $101.3M$75.1M$74.0M$72.4M$63.4M$49.7M$57.7M$30.4M$26.8M$16.9M
Total liabilities $237.3M$207.8M$478.6M$472.4M$462.5M$338.1M$145.1M$33.1M$27.6M$17.1M
Retained earnings -$933.1M-$745.4M-$599.1M-$464.4M-$365.2M-$310.1M-$189.7M-$205.1M-$192.2M-$192.1M
Total equity $656.2M$766.9M$461.8M$530.0M$587.2M$667.4M$673.3M$173.9M$138.2M$117.3M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$14.8M-$61.3M-$57.8M-$33.1M$24.7M-$23.0M-$369.0K$18.9M$26.1M$12.3M
Depreciation and amortisation $38.1M$35.6M$33.7M$31.6M$29.7M$29.4M$6.3M$6.3M$5.5M$4.7M
Stock-based compensation $63.2M$50.2M$43.5M$38.6M$30.1M$46.5M$36.4M$25.7M$17.6M$8.8M
Capital expenditure $7.7M$6.3M$20.2M$30.3M$47.8M$6.9M$4.7M$10.3M$6.3M$6.3M
Investing cash flow -$77.6M$47.8M$14.1M$44.8M-$58.2M-$205.1M$43.4M-$26.4M-$12.4M-$26.1M
Financing cash flow $11.9M$91.5M$15.0M$6.3M$39.3M$262.5M-$9.6M$21.6M$4.7M-$1.6M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-157829.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M 0 200M 400M 600M Revenue, FY2016: 114.4M Gross profit, FY2016: 98.2M Net income, FY2016: 4.5M Revenue, FY2017: 159.3M Gross profit, FY2017: 138.2M Net income, FY2017: -92K Revenue, FY2018: 181.3M Gross profit, FY2018: 156.2M Net income, FY2018: -13M Revenue, FY2019: 237M Gross profit, FY2019: 198.4M Net income, FY2019: 15.4M Revenue, FY2020: 225M Gross profit, FY2020: 133.2M Net income, FY2020: -120.3M Revenue, FY2021: 294M Gross profit, FY2021: 227.4M Net income, FY2021: -49.6M Revenue, FY2022: 282.9M Gross profit, FY2022: 213.9M Net income, FY2022: -99.2M Revenue, FY2023: 314.7M Gross profit, FY2023: 239.1M Net income, FY2023: -134.7M Revenue, FY2024: 383.5M Gross profit, FY2024: 289.5M Net income, FY2024: -146.4M Revenue, FY2025: 507.4M Gross profit, FY2025: 282.8M Net income, FY2025: -187.7M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $114.4M $159.3M $181.3M $237.0M $225.0M $294.0M $282.9M $314.7M $383.5M $507.4M
Gross profit $98.2M $138.2M $156.2M $198.4M $133.2M $227.4M $213.9M $239.1M $289.5M $282.8M
Net income $4.5M -$92.0K -$13.0M $15.4M -$120.3M -$49.6M -$99.2M -$134.7M -$146.4M -$187.7M

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%